Tech Transfer Roundup: How To Protect Downstream Rights

A review of tech transfer deals over 10 years shows that licensees often protect their value positions to limit royalties paid out to licensors. Meanwhile, licensors often protect their future rights with language recognizing that additional parties may be involved in producing a final product.

Tech Transfer regular column feature image

Risks to capturing fair value can surface for both licensors and licensees in a technology transfer deal, because the out-licensing of academic intellectual property to a start-up can be just the first part of a long, winding process before a final product is brought to market. By the time commercialization begins, the final product may comprise multiple IP components and additional parties.

Sean Sheridan, a principal with Charles River Associates, decided to review a subset of tech transfer deals over a 10-year period to determine just what types of contract provisions both...

More from Deals

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By 

Buy boosts the French major's immunology pipeline.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By 

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

More from Business